

GSK's commitment to oncology

We are seeking answers to some of the most challenging questions in cancer research.

Innovation with the goal to deliver transformational medicines

4

key areas of
cancer research

15+

clinical assets

40+

GSK-sponsored
clinical trials
currently underway



GSK Oncology is committed to the discovery of **new oncology targets** with the potential of helping patients with cancer.

GSK Oncology

Who we are

A science-led global healthcare company committed to helping those affected by cancer do more, feel better, live longer.

Our work in oncology is focused on maximizing patient survival by delivering transformational medicines.

Our values

Patient focus
Transparency
Respect
Integrity

Our expectations

Courage
Accountability
Development
Teamwork

We have a proud history of more than 300 years helping billions of people around the world.

Our goal is to be one of the world's most innovative, best performing and trusted healthcare companies.


Trademarks are owned by or licensed to the GSK group of companies.



©2020 GSK or licensor.
BLMBROC190010 January 2020
Produced in USA. 0002-0005-15



do more
feel better
live longer




GSK Oncology
Our values and expectations are at the heart of everything we do

Not an actual patient.


GSK Oncology

We have a unique R&D approach exploring multiple groundbreaking fronts to fight cancer.




Immuno-oncology

Using the human immune system to treat cancer.




Cell therapy

Engineering human T cells to target cancer.



Cancer epigenetics


Modulating the gene-regulatory system of the epigenome to exert anti-cancer effects.



Synthetic lethality

Targeting two mechanisms at the same time which together, but not alone, may have substantial effects against cancer.

Together,
we can
make a
difference



R&D and the oncology pipeline

We aim to deliver a sustainable flow of innovative treatment at the forefront of the industry.

\$5B

Globally in 2018, we invested **\$5 billion in R&D**, spanning areas core to our business and expanding our research in oncology.

15+

We have significantly progressed our oncology pipeline by **doubling the number of assets** in clinical development.



Our patient focus

Our research is focused on maximizing patient survival by delivering transformational medicines.



We believe in making **cure a possibility** for all.



Patients are our partners and priority. **We never lose sight of the fact that patients are at the core of what we do.**



We are actively seeking input and feedback to **ensure the therapies we are developing are addressing areas of unmet medical need.**



We are passionate in our pursuit of **innovative and effective treatments** and believe in leveraging the power of **patient-driven science** and technology.

Why we do it

To help people do more,
feel better, live longer.